Wednesday November 25 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

«AMH

Below is an extended AMH publications listing. Click here to return to the gene page.

Gene Information from Publications

Publication Link Summary of findings
18230658 Observational study of gene-disease association. (HuGE Navigator)
17543956 Oocytes are more likely to be fertilized when follicles are able to make high concentrations of AMH in the follicular fluid. AMH could be a prediction marker for fertilization.
12477536 Observational study of gene-disease association. (HuGE Navigator)
17636279 Observational study of gene-disease association. (HuGE Navigator)
17335955 serum anti-mullerian hormone (AMH) levels in Polysystic Ovary Syndrome patients were significantly higher than in healthy women
17559842 MIS is the earliest marker to change with agem has it has least intercycle variabilityane has the least intracycle variability; and 4) it may be informative if randomly obtained during the menstrual cycle. {REVIEW]
17485437 anti-Mullerian hormone expression is stable during the menstrual cycle
17462637 Serum AMH and inhibin B are significantly lower in the men with nonobstructive azoospermia compared to the controls.
17488788 AMH concentrations are increased in peripubertal daughters of polycystic ovary syndrome women
16030171 a relative deficiency of AMH in primordial and transitional follicles in ovaries may contribute to disordered early follicle development in polycystic ovary syndrome
15550498 AMH promoter sequence variations or the previously proposed SF3a2-AMH fusion co-transcripts cannot be responsible for aberrant AMH expression leading to Mullerian duct degradation.
16368745 AMH could thus be used as a diagnostic criterion and incorporated as such in the Rotterdam definition of polycystic ovary syndrome.
17088539 MIS in combination with selective targeted therapies might achieve greater activity against ovarian cancer than the use of each individual agent alone
12456604 poor response in IVF, indicative of a diminished ovarian reserve, is associated with reduced baseline serum AMH concentrations
16159935 Aggressive granulosa cell tumors(GCTs) retain high GATA-4 expression, whereas larger tumors lose proliferation-suppressing anti-Mullerian hormone expression. High GATA-4 expression in GCTs may serve as marker of poor prognosis.
16566934 MIS could potentially serve as a useful marker for identifying patients at risk for OHSS.
15217995 Serum AMH concentrations decrease over time both in women presenting with WHO 2 anovulatory infertility and in normal women. Decrease in WHO 2 patients is less pronounced despite distinctly elevated concentrations. May suggest retarded ovarian ageing.
14715867 serum anti-Mullerian hormone (AMH) concentrations are elevated in normogonadotropic anovulatory infertile women (WHO 2) women, especially in those patients exhibiting polycystic ovary syndrome
16740653 Mullerian inhibiting substance regulates androgen-induced gene expression and growth in prostate cancer cells through a nuclear factor-kappaB-dependent Smad-independent mechanism.
16816803 Its main physiological role is the induction of regression of Mullerian ducts in male fetuses but it also plays a role in Leydig cell steroidogenesis and in follicular development
12462075 Review. The role of AMH in gonadal development and its mutation in the persistent Mullerian duct syndrome is discussed.
17425826 Mullerian inhibiting substance has a role in response to ovarian stimulation
15536161 Recombinant follitropin and chorionic gonadotropin stimulation of the testis dramatically suppresses the secretion of AMH in hypogonadism.
14671196 Increase of anti-Mullerian hormone(AMH) serum level in polycystic ovary syndrome is consequence of androgen-induced excess in small antral follicle number, and each follicle produces normal amount of AMH.
14742691 Anti-Mullerian hormone expression pattern in the human ovary follicle.
16923748 Hence, AMH exhibits a relatively stable expression during the menstrual cycle, making it an attractive determinant of ovarian activity.
15070957 In XXY adolescents, AMH and INHB were undetectable
15897891 AMH is also a gonadal tumor suppressor which mediates its effects through a specific type II receptor and the bone morphogenetic protein (BMP)-specific Smad proteins.
14671316 Induction of p130 and p107 play an important role in the inhibition of growth of C33A cells by MIS.
11773638 Administration of MIS to male mice induced IEX-1S mRNA in the prostate in vivo, suggesting that MIS may function as an endogenous hormonal regulator of NF-kappaB signaling and growth in the prostate gland.
16213847 Increased MIS production in adolescent girls may represent an early manifestation of polycystic ovary syndrome
17337470 Polymorphisms in the AMH and AMHR2 genes are associated with follicular phase E(2) levels, suggesting a role for AMH in the regulation of FSH sensitivity in the human ovary.
12571168 results indicate that serum AMH levels are strongly correlated with ovarian follicular status during the early follicular phase

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.